I agree that this site is using cookies. You can find further informations here.
X
Minal Barve
93  results:
Search for persons X
?
1

A Relative Bioavailability, Bioequivalence, and Food Effect..:

Falchook, Gerald ; Patnaik, Amita ; Richardson, Debra L....
Clinical Therapeutics.  46 (2024)  3 - p. 228-238 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Phase 1b study to assess the safety, tolerability, and clin..:

Stradella, Agostina ; Johnson, Melissa ; Goel, Sanjay...
Cancer Medicine.  13 (2024)  13 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
3

Efficacy and Safety of Adagrasib plus Cetuximab in Patients..:

Yaeger, Rona ; Uboha, Nataliya V. ; Pelster, Meredith S....
Cancer Discovery.  14 (2024)  6 - p. 982-993 , 2024
Link: https://doi.org/10.1158/..
 
?
4

A phase Ib study evaluating the recommended phase II dose, ..:

Juric, Dejan ; Barve, Minal ; Vaishampayan, Ulka...
Cancer Medicine.  13 (2024)  5 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
5

OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine K..:

Heymach, John ; Yamamoto, Noboru ; Opdam, Frans...
Journal of Thoracic Oncology.  19 (2024)  7 - p. e1 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Pharmacokinetic study of capivasertib and the CYP3A4 substr..:

Miller, Claire ; Sommavilla, Roberto ; O'Bryant, Cindy L....
Cancer Chemotherapy and Pharmacology.  , 2024
Link: https://doi.org/10.1007/..
 
?
7

Safety, pharmacokinetics, pharmacodynamics, and antitumor a..:

Baranda, Joaquina C. ; Robbrecht, Debbie ; Sullivan, Ryan...
Clinical and Translational Science.  17 (2024)  6 - p. , 2024
Link: https://doi.org/10.1111/..
 
?
8

First-in-human study of oleclumab, a potent, selective anti..:

Bendell, Johanna ; LoRusso, Patricia ; Overman, Michael...
Cancer Immunology, Immunotherapy.  72 (2023)  7 - p. 2443-2458 , 2023
Link: https://doi.org/10.1007/..
 
?
9

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-C..:

Scarfò, Lydia ; Patel, Manish R. ; Eyre, Toby A....
HemaSphere.  7 (2023)  S3 - p. e852670f , 2023
Link: https://doi.org/10.1097/..
 
?
10

Practical Guidance for the Management of Adverse Events in ..:

Zhang, Jun ; Johnson, Melissa ; Barve, Minal...
The Oncologist.  28 (2023)  4 - p. 287-296 , 2023
Link: https://doi.org/10.1093/..
 
?
11

BETA prime: a first-in-man phase 1 study of AdAPT-001, an a..:

Conley, Anthony P. ; Roland, Christina L. ; Bessudo, Alberto...
Cancer Gene Therapy.  31 (2023)  4 - p. 517-526 , 2023
Link: https://doi.org/10.1038/..
 
?
12

A Phase I, Open-Label, Dose Confirmation, Escalation, and E..:

Heymach, John ; Opdam, Frans ; Barve, Minal...
Clinical Lung Cancer.  24 (2023)  2 - p. e65-e68 , 2023
Link: https://doi.org/10.1016/..
 
?
13

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and c..:

Kesari, Santosh ; Bessudo, Alberto ; Gastman, Brian R...
Future Oncology.  18 (2022)  29 - p. 3245-3254 , 2022
Link: https://doi.org/10.2217/..
 
?
14

CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Re..:

Coombs, Catherine C. ; Pagel, John M. ; Shah, Nirav N....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S268-S269 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, N..:

Cohen, Jonathon B. ; Shah, Nirav N. ; Alencar, Alvaro J....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S118 , 2022
Link: https://doi.org/10.1016/..
 
1-15